1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Complete 2015-16 Induced Pluripotent Stem Cell Industry Report

Complete 2015-16 Induced Pluripotent Stem Cell Industry Report

  • April 2015
  • 175 pages
  • ID: 3321312
  • Format: PDF
  • By BioInformant Worldwide, L.L.C.

Summary

Table of Contents

Report Applications

This global strategic report is produced for:

Management of Stem Cell Product Companies
Management of Stem Cell Therapy Companies
Stem Cell Industry Investors
It is designed to increase your efficiency and effectiveness in:

Commercializing iPSC products, technologies, and therapies
Making intelligent investment decisions
Launching high-demand products
Selling effectively to your client base
Increasing revenue
Taking market share from your competition

Executive Summary

Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more Conditions such as Huntington’s disease, Parkinson’s disease, and spinal cord injuries are examples of clinical applications in which stem cells could offer benefits in halting or even reversing damage

Traditionally, scientists have worked with both embryonic and adult stem cells for research tools, as well as for cellular therapy While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral, and spiritual controversy surrounding their use Although some adult stem cells do have differentiation capacity, it is often limited in nature, which results in fewer options for use Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics

Discovery of Induced Pluripotent Stem Cells

Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs) These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods Research and experimentation using mouse cells by Shinya Yamanaka’s lab at Kyoto University in Japan was the first instance in which there was successful generation of iPSCs In 2007, a series of follow-up experiments was done at Kyoto University in which human adult cells were transformed into iPSCs Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells

Continued research and experimentation have resulted in numerous advances over the last few years For example, several independent research groups have announced that they have derived human cardiomyocytes from iPSCs These cells could be used in a laboratory context to test drugs that treat arrhythmia and other cardiac conditions, and in a clinical context they could potentially be implanted into patients with heart disorders

Similar advances will continue to be perfected for use of reprogrammed adult cells in the treatment of other diseases and disorders Original techniques for iPSC production, such as viral induced transcription processes, are being replaced with newer technologies as private industry joined with the scientific community to develop safer and more efficient methods of iPSC production As innovation around methods of iPSC production continues, clinical grade production of industrial quantities of iPSCs is now becoming possible due to sustained research and experimentation

Therapeutic Applications of Induced Pluripotent Stem Cells

While there has been continued excitement at the prospect of what such artificially re-manufactured cells could contribute to medical advances, there have also been setbacks along the way By 2010, there were a number of private companies that were ready to capitalize on the breakthrough technology that iPSCs represent One such company, Advanced Cell Technology (ACT) in Marlborough, Massachusetts, discovered several problematic issues while conducting experiments for the purpose of applying for US Food and Drug Administration approval to use iPSCs in therapeutic applications Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced

As a result, ACT (now named “Ocata Therapeutics”) has shifted its induced pluripotent stem cell approach to producing iPSC derived human platelets One of the benefits of a platelet-based product is that platelets do not contain nuclei, and therefore, cannot divide or carry genetic information While nothing is completely safe, iPSC derived platelets are likely to be substantially safer than other currently available iPSC therapies, in which uncontrolled proliferation may be a concern It also shifted to using embryonic stem cells for clinical trial purposes, despite the ethical concerns surrounding this cell type

Over the next few years, iPSC research advances accelerated exponentially, with perhaps the most momentous milestone being the launch of the first clinical research trial ever involving the transplant of autologous iPSCs into humans (“autologous” meaning the cells are both derived and implanted into the same patient) Previously, all clinical trials using iPSCs involved only the creation of iPSC lines from specific patient populations and subsequent evaluation of these lines for determining whether they could represent a good “model” for a disease of interest within that population

Therefore, 2013 was the first time in which clinical research involving transplant of iPSCs into humans was initiated, led by Masayo Takahashi of the RIKEN Center for Developmental Biology in Kobe, Japan Dr Takahashi and her team are investigating the safety of iPSC-derived cell sheets in patients with wet-type age-related macular degeneration While the trial was initiated in 2013 and production of iPSCs from patients began at that time, it was not until August of 2014 that the first patient, a Japanese woman, was implanted with retinal tissue generated using iPSCs derived from her own skin cells A team of three eye specialists, led by Yasuo Kurimoto of the Kobe City Medical Center General Hospital, implanted a 13 by 30mm sheet of iPSC-derived retinal pigment epithelium cells into the patient’s retina Preliminary results are indicating positive results for the participants in this iPSC clinical trial

Key Report Findings


Induced pluripotent stem cells represent one of the most promising research advances within the past decade, making this a valuable report for both executives and investors to use to optimally position themselves to sell iPSC products To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage of crucial iPSC trends

Key report findings include:

Metrics, Timelines, Tables, and Graphs for the iPSC Industry
Trend Rate Data for iPSC Grants, Clinical Trials, and Scientific Publications
Analysis of iPSC Patent Environment, including Key Patents and Patent Trends
Market Segmentation
5-Year Market Size Projections (2015-2019)
Market Size Estimations, by Market Segment
Updates on Crucial iPSC Industry and Technology Trends
Analysis of iPSC Market Leaders, by Market Segment
Geographical Assessment of iPSC Innovation
SWOT Analysis for the iPSC Sector (Strengths, Weaknesses, Opportunities, Threats)
Preferred Species for iPSC Research
Influential Language for Selling to iPSC Scientists
Breakdown of the Marketing Methods, including Exposure and Response Rates

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Single Use Assemblies Market by Product, Application, Solution, End User - Global Forecast to 2024

Single Use Assemblies Market by Product, Application, Solution, End User - Global Forecast to 2024

  • $ 4950
  • December 2019

Increasing demand for biopharmaceuticals and rising life science R&D expenditure in biopharmaceuticals is expected to drive the overall growth of the single-use assemblies market.The single-use assemblies ...

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral ...

In Vitro Lung Model Market to 2027- Global Analysis and Forecasts by Type; Application and Geography

In Vitro Lung Model Market to 2027- Global Analysis and Forecasts by Type; Application and Geography

  • $ 4550
  • November 2019

The global in vitro lung model market is expected to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018. The market is estimated to grow with a CAGR of 16.2% from 2019-2027.Driving factors of the in ...


ref:plp2015

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on